SCCS Preliminary Opinion on Kojic Acid
In 2019, the European Commission set out two lists of ingredients suspected of having endocrine disrupting properties. Kojic Acid was included in group A (higher priority) and the European Commission asked the SCCS to carry out a safety assessment on this ingredient. The SCCS has published its preliminary opinion on Kojic Acid and the deadline for comments was set at 14 January 2022.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate


Kojic Acid is a heterocyclic compound and is a secondary metabolite commonly produced by many species of filamentous fungi (like Aspergillus and Penicillium). In cosmetics and personal care products, Kojic Acid is used as an antioxidant and bleaching agent. Due to its inhibitory effect on tyrosinase activity and melanogenesis, Kojic acid has been widely used as a skin lightening/whitening or depigmenting agent in cosmetics. Kojic Acid is not currently included in the annexes of the European Cosmetics Regulation (No. 1223/2009), which means its use is not restricted in cosmetic products.

In 2010, the Cosmetic Ingredient Review (CIR) Expert Panel has assessed the safety of Kojic Acid and concluded that it was safe for use in cosmetic products, up to a maximum concentration of 1%. The Panel considered that the two endpoints of concern (dermal sensitization and skin lightening) would not be seen at use concentrations below 1%.

The Scientific Committee on Consumer Products (SCCP) issued its first opinion on the safety of Kojic Acid in 2008. The Committee concluded that, based on the information provided and the calculation of margins of safety (MoS), the use of Kojic Acid at a maximum concentration of 1.0% in skin care formulations poses a risk to the health of consumers and that Kojic Acid had the potential to induce skin sensitization. SCCP asked for the submission of relevant data on kinetics of the ingredient (after dermal application) in order to refine the MoS approach.

A new dermal penetration study and the industry response was presented and in 2012 the European Commission’s Scientific Committee on Consumer Safety (SSCS) issued a second opinion on Kojic Acid. The SCCS stated that “re-examination of the available data for Kojic Acid, used as a skin whitening agent at a concentration of 1.0% in leave-on creams, which are generally applied to the face and/or hands leads to the conclusion that it is safe for the consumers”. No conclusion was drawn on the derivatives of Kojic Acid (e.g., esters of Kojic Acid, Kojic Acid dipalmitate, Kojic Acid isopalmitate and chloro-Kojic Acid), as no data was submitted on these. Moreover, the Committee considered that a concern on the use of Kojic Acid arises when the human skin barrier is weakened (e.g., after peeling) or when the ingredient is applied on larger skin surfaces.


In early 2019, a priority list of 28 potential endocrine disruptors (not already covered by the bans of cosmetic regulation) was established by the Commission. From these 28 substances, 14 were considered as higher priority (Group A) and the other 14 were included in the low priority group (Group B). The public call for data for the considered higher priority substances was carried out in 2019. Kojic Acid was included in Group A. (see previous post)

During the call for data, stakeholders submitted scientific evidence to demonstrate the safety of Kojic Acid in cosmetic products. The European Commission asked the SCCS to carry out a safety assessment on Kojic Acid considering the data submitted.

At its plenary meeting in October, the SCCS issued a preliminary opinion on Kojic Acid. Considering the concerns related to potential endocrine disrupting properties of Kojic Acid, the SCCS is of the opinion that “the concentration of 1% Kojic acid is not safe for the intended use in cosmetic products”. Moreover, the SCCS was unable to advice on the safe concentration of Kojic Acid in individual cosmetic products. For example, Kojic Acid should not exceed 0.04% if a face cream and hand cream are combined on a twice a day use.

Kojic Acid is sometimes added to peeling agents and a weakened skin barrier may be of additional concern due to increased dermal penetration.

The SCCS preliminary opinion is open for comments until 14 January 2022.

If you wish to get more information on the safety of cosmetic ingredients, feel free to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Scientific Committee on Consumer Safety (SCCS). Opinion on Kojic Acid. SCCP/1182/08. 2008
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on Kojic Acid. SCCS/1481/12. 2012
  4. Scientific Committee on Consumer Safety (SCCS). Opinion on Kojic Acid. SCCS/1637/21. Preliminary version. 2021


news & updates

EU Ecolabel adoption and recognition are on the rise

The Ecolabel certification is a comprehensive program focused on fostering sustainable practices. It evaluates products based on life cycle assessments, where every phase of said life cycle must abide by strict standards to attain the Ecolabel certification. The overarching objective of this certification is minimizing environmental harm from production or consumption activities.

Read More »
news & updates

SCCS preliminary opinion on Citral sensitization endpoint

Ingredients: CITRAL

Date of publication: 27/03/2024

On March 27 2024, the Scientific Committee on Consumer Safety (SCCS) published the Preliminary Opinion on the safety of Citral in cosmetic products. The deadline for comments is set to June 2, 2024.

Read More »
cosmetic products

UK proposes ban of wet wipes containing plastic 

The UK has proposed, on April 24, 2024, a regulation titled The Environmental Protection (Wet Wipes Containing Plastic) (England) Regulations 2024, to the World Trade Organization (WTO). The regulation aims to eliminate the supply and sale of plastic-containing wet wipes, including cosmetic ones. The public can offer comments on the draft until June 23, 2024, with adoption expected in September of the same year.

Read More »
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »